| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
,
* From the Departments of Pharmacology, West China School of Pharmacy, Sichuan University; and
Anesthesiology, West China Hospital, Sichuan University; and the
State Key Laboratory of Biotherapy of Cancer, Chengdu, Sichuan, P.R. China.
Address correspondence to: Dr. Jin Liu, Department of Anesthesiology, West China Hospital, Sichuan University, 610041, Chengdu, P.R. China. Phone: 86-28-8542-2520; E-mail: scuanesth{at}hotmail.com
Purpose: Remifentanil is known to cause vasodilation at standard anesthetic concentrations. The intracellular mechanisms underlying its vasodilator action may involve the activation of ion channels. The purpose of this study was to examine whether remifentanil inhibits L-type calcium channels (Ca.L) and provides dose-dependent effects on L-type calcium channel Ba2+ currents (IBa.L) in human mesenteric arterial smooth muscle cells.
Methods: Using the whole-cell patch-clamp method, an indepth analysis of the mechanism of the IBa.L induced by remifentanil was performed in cells which were enzymatically isolated from human mesenteric arterial smooth muscle. Ten millimolars Ba2+ was used to replace 1.5 mM Ca2+ to increase the amplitude of the inward current through Ca2+channels. L-type calcium channel Ba2+ was elicited during 50 msec depolarizing test pulses (150 msec duration) to +80 mV (10 mV increments) from a holding potential of -60 mV. The effects of remifentanil on Ca.L were observed at the following concentrations: 1.21, 4.84, and 19.4 nmol·L–1 and were compared with control.
Results: Remifentanil produced a concentration-dependent block of IBa,L with IC50 values of 38.90 ± 3.96 x 10–3 µmol·L–1. The L-type calcium channel blocker, nifedipine, antagonized these remifentanil-induced currents. Remifentanil, at all concentrations, shifted the maximum of the current-voltage relationship in the hyperpolarizing direction of IBa.L.
Conclusion: Remifentanil significantly inhibits Ca.L channels in a concentration-dependent manner in human mesenteric arteriolar smooth muscle cells.
1 Elliott P, O’Hare R, Bill KM, Phillips AS, Gibson FM, Mirakhur RK. Severe cardiovascular depression with remifentanil. Anesth Analg 2000; 91: 58–61.
2 Kazmaier S, Hanekop GG, Buhre W, et al. Myocardial consequences of remifentanil in patients with coronary artery disease. Br J Anaesth 2000; 84: 578–83.
3 Ouattara A, Boccara G, Kockler U, et al. Remifentanil induces systemic arterial vasodilation in humans with a total artificial heart. Anesthesiology 2004; 100: 602–7.[Medline]
4 Chanavaz C, Tirel O, Wodey E, et al. Haemodynamic effects of remifentanil in children with and without intravenous atropine. An echocardiographic study. Br J Anaesth 2005; 94: 74–9.
5 Joshi GP, Warner DS, Twersky RS, Fleisher LA. A comparison of the remifentanil and fentanyl adverse effect profile in a multicenter phase IV study. J Clin Anesth 2002; 14: 494–9.[Medline]
6 Sebel PS, Hoke JF, Westmoreland C, Hug CC Jr, Muir KT, Szlam F. Histamine concentrations and hemodynamic responses after remifentanil. Anesth Analg 1995; 80: 990–3.[Abstract]
7 Shinohara K, Aono H, Unruh GK, Kindscher JD, Goto H. Suppressive effects of remifentanil on hemodynamics in baro-denervated rabbits. Can J Anesth 2000; 47: 361–6.
8 Noseir RK, Ficke DJ, Kundu A, Arain SR, Ebert TJ. Sympathetic and vascular consequences from remifentanil in humans. Anesth Analg 2003; 96: 1645–50.
9 Unlugenc H, Itegin M, Ocal I, Ozalevli M, Guler T, Isik G. Remifentanil produces vasorelaxation in isolated rat thoracic aorta strips. Acta Anaesthesiol Scand 2003; 47: 65–9.[Medline]
10 Jackson WF. Ion channels and vascular tone. Hypertension 2000; 35: 173–8.
11 Smirnov SV, Aaronson PI. Ca2+-activated and voltage- gated K+ currents in smooth muscle cells isolated from human mesenteric arteries. J Physiol 1992; 457: 431–54.
12 Smirnov SV, Aaronson PI. Ca2+ currents in single myocytes from human mesenteric arteries: evidence for a physiological role of L-type channels. J Physiol 1992; 457: 455–75.
13 Wilde DW, Furspan PB, Szocik JF. Calcium current in smooth muscle cells from normotensive and genetically hypertensive rats. Hypertension 1994; 24: 739–46.[Abstract]
14 Reves JG. Educational considerations for the clinical introduction and use of remifentanil. Anesth Analg 1999; 89(4 Suppl): S4–6.[Medline]
15 Lang E, Kapila A, Shlugman D, Hoke JF, Sebel PS, Glass PS. Reduction of isoflurane minimal alveolar concentration by remifentanil. Anesthesiology 1996; 85: 721–8.[Medline]
16 Borgland SL, Connor M, Osbourne PB, Furness JB, Christie MJ. Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J Biol Chem 2003; 278: 18776–84.
17 Nomura K, Reuveny E, Narahashi T. Opioid inhibition and desensitization of calcium channel currents in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1994; 270: 466–74.
18 Jin W, Lee NM, Loh HH, Thayer SA. Dual excitatory and inhibitory effects of opioids on intracellular calcium in neuroblastoma x glioma hybrid NG108-15 cells. Mol Pharmacol 1992; 42: 1083–9.[Abstract]
19 Xiao RP, Spurgeon HA, Capogrossi MC, Lakatta EG. Stimulation of opioid receptors on cardiac ventricular myocytes reduces L-type Ca2+ channel current. J Mol Cell Cardiol 1993; 25: 661–6.[Medline]
20 Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y. Distinct components of morphine effects on cardiac myocytes are mediated by the kappa and delta opioid receptors. J Mol Cell Cardiol 1997; 29: 711–20[Medline]
21 Xiao GS, Zhou JJ, Wang GY, Cao CM, Li GR, Wong TM. In vitro electrophysiologic effects of morphine in rabbit ventricular myocytes. Anesthesiology 2005; 103: 280–6.[Medline]
22 Garaulet JV, Laorden ML, Milanes MV. Effect of chronic administration of dihydropyridine Ca2+ channel ligands on sufentanil-induced tolerance to mu- and kappa-opioid agonists in the guinea pig ileum myenteric plexus. Regul Pept 1996; 63: 1–8.[Medline]
23 Zhang Y, Irwin, MG, Wong TM, Chen M, Cao CM. Remifentanil preconditioning confers cardioprotection via cardiac kappa- and delta-opioid receptors. Anesthesiology 2005; 102: 371–8.[Medline]
24 Connor M, Osborne PB, Christie MJ. Mu-opioid receptor desensitization: is morphine different? Br J Pharmacol 2004; 143: 685–96.[Medline]
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
